OS data remain immature (crossover-adjusted HR = 0.80; HR 0.41; p < 0.0001), yet the consistency of efficacy and safety across both VISION and PSMAfore supports the integration of PSMA-targeted radioligand therapy not only after but also before taxane chemotherapy, further consolidating PSMA as a central biomarker and therapeutic target in advanced prostate cancer [72]. This evidence concerns the gene FOLH1 and prostate carcinoma.